<DOC>
	<DOC>NCT03087487</DOC>
	<brief_summary>The primary objectives of this study are to compare the risk of major bleeding and stroke/systemic embolism (SE) events among oral anticoagulant (OAC)-na√Øve non-valvular atrial fibrillation (NVAF) patients initiating OAC warfarin or apixaban treatment.</brief_summary>
	<brief_title>Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1. Had 1 or more pharmacy claim for apixaban or warfarin during the identification period (01Jan2013 to 30Sep2015). The first apixaban or warfarin pharmacy claim date during the identification period will be designated as the index date 2. Patients 18 years old or older as of the index date 3. At least 1 diagnosis of atrial fibrillation prior to or on index date, identified by any medical claim 4. At least 12 months of baseline period prior to index date with continuous enrollment 1. Evidence of valvular heart disease, transient atrial fibrillation, venous thromboembolism during the 12month baseline period or on the index date 2. Evidence of pregnancy during the study period 3. Had a pharmacy claim for warfarin, apixaban, dabigatran, rivaroxaban, or edoxaban during the 12month baseline period 4. Had more than 1 oral anticoagulant claim on the index date</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>